The treatment of fmk inhibits partially the phosphorylation of RSK2 at Ser386 in human t (4; 14)-positive, FGFR3-expressing myeloma cell lines KMS11 and OPM (46), indicating that fmk cannot completely inhibit the RSK2 C-terminal kinase activity. Here, RPS6KA3 is linked to plasma cell myeloma.